OTQ-923

N/A

Report date: 2025/07/30 13:53:55

Base Information

Drug NameOTQ-923

Drug Alias NameOTQ-923

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9

Mechanisms of ActionHemoglobin subunit gamma-1 inhibitorsHemoglobin subunit gamma-2 inhibitors

TargetsHemoglobin subunit gamma-1Hemoglobin subunit gamma-2

Therapy Area/IndicationsAnemia, Sickle Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIntellia Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIntellia Therapeutics Inc Novartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsAnemia, Sickle Cell

Other Information

ATC CodeN/A